Urgent.News

What's breaking now, across hundreds of outlets.

Health & Medicine

Analysis of antimicrobial resistance in the LAKANA trial of azithromycin administration in Mali: A sub-study of a cluster randomized clinical trial

by Jane Juma, Juho Luoma, Awa Traore, Aminata Sangare, Oumou Bouare, Fadima Cheick Haidara, Oumar Samaké, Laura Adubra, Rikhard Ihamuotila, Owen Martell, Tiia Haapaniemi, Kaisa Ylikruuvi, Camilla Ducker, Ulla Ashorn, Samba Sow, Per Ashorn, Yin Bun Cheung, Nigel Klein, Elaine Cloutman-Green, Yue-Mei Fan, Dagmar G. Alber Background Mass azithromycin administration has been used to reduce under-five…

The Large-scale Assessment of the Key health-promoting Activities of two New mass drug administration regiments with Azithromycin (LAKANA) trial in Mali aimed to evaluate the impact of azithromycin administration on antimicrobial resistance (AMR) in children. The study, conducted from 2015 to 2018, randomly assigned infants aged 1-11 months to receive placebo, twice-yearly, or quarterly azithromycin for 2 years. The results revealed no mortality benefit among treated children.

The current sub-study focused on AMR outcomes by collecting repeated cross-sectional nasopharyngeal and rectal swabs from children aged 4-14 months and untreated contacts aged 49-59 months at various time points. The samples were analyzed for resistance to macrolide and non-macrolide antibiotics in Streptococcus pneumoniae and Escherichia coli.

At baseline, among 4-14-month-old children, macrolide resistance in S. pneumoniae was found to be 16.6% in the placebo group, 15.5% in the twice-yearly group, and 11.1% in the quarterly azithromycin group. For E. coli, the respective resistances were 5.0%, 5.0%, and 0.0%. At 36 months, the prevalences increased slightly to 13.4% in placebo, 14.5% in twice-yearly, and 17.2% in quarterly azithromycin groups for S. pneumoniae, and 5.1%, 6.4%, and 9.1% for E. coli.

The differences between placebo and twice-yearly groups were 1.0% for S. pneumoniae and 1.3% for E. coli, while the quarterly group showed increases of 3.8% for S. pneumoniae and 4.0% for E. coli.

Among untreated older children, there were no significant differences in macrolide resistance at baseline or 24 months. The study's findings suggest that twice-yearly azithromycin administration to infants did not increase AMR in treated children or contacts and met the predefined noninferiority margin. However, the quarterly administration could not rule out a modest dose-dependent increase in AMR for S. pneumoniae and E. coli.

Rewritten by urgent.news; may contain errors — check the original.

Source: journals.plos.org

Read the original at journals.plos.org →

Report a problem with this story

More in Health & Medicine

More from Friday 13 November →